NCI-H82細(xì)胞

是否是腫瘤細(xì)胞： 1

物種來(lái)源： 人

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

年限： 40 years

運(yùn)輸方式： 凍存運(yùn)輸

ATCC Number： HTB-175?

相關(guān)**： 小細(xì)胞肺癌

器官來(lái)源： 肺

細(xì)胞形態(tài)： 上皮樣

數(shù)量： 大量

Designations: NCI-H82 [H82]

Depositors: NCI-H82細(xì)胞 AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: carcinoma; small cell lung cancer

Derived from metastatic site: pleural effusion

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Receptors: insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP)

Tumorigenic: Yes

Oncogene: myc +; myb -; raf +; ras +; fms +; fes +

NCI-H82細(xì)胞DNA Profile (STR): Amelogenin: X

CSF1PO: 11

D13S317: 8

D16S539: 12

D5S818: 12

D7S820: 10,13

THO1: 9,9.3

TPOX: 11

vWA: 14

Cytogenetic Analysis: This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1

Me-2, 1

PGM1, 1-2

PGM3, 1-2

Age: 40 years

Gender: male

Ethnicity: NCI-H82細(xì)胞Caucasian

Comments: The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung.

The morphology of the original tumor was not characteristic of SCLC.

The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase.

It does not have detectable levels of L-DOPA decarboxylase or bombesin.

The cells produce an abnormally sized p53 mRNA (3.7 kb).

C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells.

The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern.

The cells stain positively for neurofilaments and vimentin.

There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended

Medium Renewal: 2 to 3 times per week

This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium.

Preservation: Culture medium, 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: NCI-H82細(xì)胞A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141

23042: Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067

23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258

23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389

32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760

32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024